previous serious infections, recurrent infections, or demyelinating disease. Switch to an IL-17i biologic over adding MTX to an IL-12/23i biologic (PICO 37). Very low Conditional recommendation based on very-low-quality evidence; may consider adding MTX in patients with only partial response to the current therapy or in those who potentially have not had enough time to adequately respond. * Active psoriatic arthritis (PsA) is defined as disease causing symptoms at an unacceptably bothersome level as reported by the patient, and judged by the examining clinician to be due to PsA based on ≥1 of the following: swollen joints, tender joints, dactylitis, enthesitis, axial disease, active skin and/or nail involvement, and extraarticular inflammatory manifestations such as uveitis or inflammatory bowel disease. IL-17i = interleukin-17 inhibitor; TNFi = tumor necrosis factor inhibitor; MTX = methotrexate. † When there were no published studies-as was the case with all of the recommendations